Navigation Links
Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
Date:9/2/2008

s were minor bleeds at the venous access

site. The incidence of additional minor events, including headache,

dizziness, nausea, fatigue and hypotension, was similar to placebo.

"Our studies consistently have confirmed the two major attributes of the REG1 system, rapid anticoagulant activity and rapid and predictable reversal of this effect," stated David J. Mazzo, Ph.D., President and Chief Executive Officer of Regado Biosciences. "Based on the encouraging Phase I study data, we anticipate results from our ongoing Phase IIa studies evaluating REG1 in

patients undergoing elective PCI will further confirm that REG1 has the potential to replace standard heparin therapy."

"In striving to meet the needs of individual patients in varied and oftentimes complex settings, it is essential for physicians to quickly, safely and effectively achieve the desired anticoagulation effect and, when required for specific clinical indications, to attenuate or fully reverse this effect," stated Richard C. Becker, M.D., Professor of Medicine, Duke University Medical Center, and Director, Duke Cardiovascular Thrombosis Center, Duke Clinical Research Institute. "As we enter a new era of anticoagulant pharmacotherapy, a therapeutic system offering these attributes would be of great benefit and may have a profound impact on patient care."

Clinician-scientists from the Duke Clinical Research Institute (DCRI) and Regado evaluated REG1 in three Phase I studies: Phase Ia, a healthy volunteer drug dose-escalating pharmacokinetic-pharmacodynamic (PK-PD) study; Phase Ib, a drug dose-escalating study in subjects with stable coronary artery disease who were receiving aspirin with or without clopidogrel; and Phase Ic, a multiple exposure, dose-ranging study in 39 healthy volunteers. Top-line results from these three studies were presented last year at the American Heart Association's 2007 Scientific Sessions and subsequently published in top-tier scientifi
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
2. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
3. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
4. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
7. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
8. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
9. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
10. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
11. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... and SAN DIEGO , Dec. ... PHG ; AEX: PHIA) and Volcano Corporation (NASDAQ: ... measurement solutions for cardiovascular applications, today announced that they have ... Philips will commence a tender offer to acquire all of ... per share, or a total equity purchase price of USD ...
(Date:12/17/2014)... NASHVILLE, Tenn. , Dec. 17, 2014  Strategic ... health management software solutions, today announced a strategic agreement ... the New Jersey regional marketplace.  ... and enhance the health and wellness solutions QualCare brings ... and the surrounding region. QualCare ...
(Date:12/17/2014)... SCOTTSDALE, Ariz. , Dec. 17, 2014 /PRNewswire/ ... of state-of-the-art interactive music products, today announced that ... Ltd, a leading manufacturer and supplier of innovative ... As part of the agreement, RSL ... Facility bundled solution specifically configured for use within ...
Breaking Medicine Technology:Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 2Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 3Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3
... LITTLE FALLS, N.J., Nov. 5 CANTEL MEDICAL CORP. ... Krakauer, President & CEO, will be presenting at the Sidoti ... formal presentation is scheduled for 9:05 AM ET on Friday, ... a Q & A session immediately following the presentation. In ...
... Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) today announced ... voreloxin orphan drug designation for the treatment of acute ... 2 clinical trials of voreloxin in AML: a single-agent ... elderly AML patients unlikely to benefit from standard induction ...
Cached Medicine Technology:Sunesis' Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia 2Sunesis' Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia 3
(Date:12/21/2014)... (PRWEB) December 21, 2014 As ... alleging heart attacks, stroke and blood clots from using ... increase, a new study shows that the male hormone ... cancer. In a study published in the Proceedings of ... James Amos-Landgraf examined a group of male rats with ...
(Date:12/21/2014)... Concept Plus, LLC. a SDB and 8(a) ... VA., today announced it has been recognized by Washington ... ranks the fastest growing government contracting small businesses by calculating ... This is the first year that Concept Plus, LLC., participated ... a 95.92% compound annual growth rate. “For Concept Plus to ...
(Date:12/20/2014)... (PRWEB) December 21, 2014 MissyDress, a ... for all prom lovers. The business has drastically cut ... prom dresses to everyone until Jan. 30, 2015. Many ... dresses, sweetheart dresses, V-neck dresses, lace dresses, and more. ... are not there every day. Whether A-line princess prom ...
(Date:12/20/2014)... Dress company LunaDress has recently announced its ... Christmas Sale, offering big discounts on all of its special ... idea to own a perfect wedding gown. If you have ... then come to LunaDress. Many different wedding dress styles and ... website now and enjoy the current special offer, up to ...
(Date:12/20/2014)... SATURDAY, Dec. 20, 2014 (HealthDay News) -- The holidays ... when they contend with fresh trees, scented candles and ... and on the decorations that have been packed away ... in my allergy and asthma patients," Dr. Rachna Shah, ... School of Medicine, said in Loyola news release. ...
Breaking Medicine News(10 mins):Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 4Health News:Concept Plus, LLC. Named One of Washington Technology’s Fast 50 2Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2Health News:2015 Collection of Wedding Dresses from LunaDress Online on Sale Now 2Health News:Holiday Trimmings Can Trigger Allergies 2
... of uterine cancer. According to the statistics it was found ... cases//. Hence the Brazilian government plans to test the new ... then the government plans to release the vaccine in the ... to vaccinate Brazilian women against the human Papilloma virus (HPV). ...
... is endemic to the eastern Democratic Republic of Congo where ... not diagnosed at an initial stage then proves to be ... then the patient can be completely cured with antibiotics. ... and this highly contagious disease is spreading like a wild ...
... alpha-synuclein, in the brain, in is considered to be ... a postdoctoral scientist , at the Whitehead Institute in Cambridge, ... are investigating the ways of preventing formation of these clumps, ... prevent the death of neurons, whose deterioration results in ...
... drug promises to slow down the progress of the dreadful ... 3,00,000 Americans were found to be affected by the fatal ... the skin and in many times it completely damages the ... have lung damaged more often it includes women only. ...
... in Ireland, suicide is the most popular cause of ... were 431 registered suicides in 2005,with approximately 6% of those recorded ... to the media not to sensationalize suicides, adding that ... , , “We are sensing that there is ...
... an increase rise in the obesity and diabetic rate ... in their life expectancy. //This has also pressurized the ... rates from cancer declined about 14 % and also ... that that average life expectancy for Australians, at 78 ...
Cached Medicine News:Health News:Breakthrough In Parkinson's research 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: